ATAI
Atai Beckley N.VNASDAQHealthcare$3.79+2.43%ClosedMarket Cap: $714.9M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
5.37
P/S
174.83
EV/EBITDA
-5.59
DCF Value
$0.18
FCF Yield
-16.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.3%
Operating Margin
-2789.5%
Net Margin
-16142.0%
ROE
-389.7%
ROA
-221.0%
ROIC
-39.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.1M | $-544.8M | $-1.73 |
| FY 2025 | $4.1M | $-660.0M | $-2.91 |
| Q3 2025 | $749.0K | $-61.1M | $-0.28 |
| Q2 2025 | $719.0K | $-27.7M | $-0.14 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2026-03-17NeedhamBuy
2026-03-09Canaccord GenuityBuy
2025-10-22HC Wainwright & Co.Buy
2025-09-23HC Wainwright & Co.Buy
2025-07-30Trading Activity
Insider Trades
View AllFeilding-Mellen Cosmodirector
SellWed Nov 26
Feilding-Mellen Cosmodirector
SellWed Nov 26
HERSHBERG ROBERTdirector
SellThu Nov 06
HERSHBERG ROBERTdirector
SellThu Nov 06
HERSHBERG ROBERTdirector
SellThu Nov 06
Company Info
Sector
Healthcare
Industry
—
Country
NL
Exchange
NASDAQ
Beta
1.57
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.